Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.

Brought to you by Elanco™

Participants

  • Mark Epstein, DVM, DABVP (C/F), CVPP, Senior Partner/Medical Director, Total Bond Veterinary Hospitals, PC
  • Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, CCRT, DACVSMR, Surgeon, Animal Surgical Clinic of Seattle, Faculty, Canine Rehabilitation Institute
  • Duncan Lascelles, BSc, BVSc, PhD, MRCVS, CertVA, DSAS (ST), DECVS, DACVS, Professor of Small Animal Surgery and Pain Management, North Carolina State University
  • Sandra Perkowski, VMD, PhD, DACVAA, Head of Anesthesia Service, Hope Veterinary Specialists
  • William Ryan, BVSc, MBA, MRCVS, Moderator

Canine Osteoarthritis: Optimizing Diagnosis and Disease Management

Managing OA in dogs continues to present a challenge. Among the issues that the veterinarian faces is the need to recognize the disease early—and educate the owner that intervening at the outset of clinical signs is warranted. Other challenges include instituting effective control of pain and inflammation and balancing this with potential side effects of chronic or long-term therapies. This expert panel addresses the current state of the art in detecting and treating OA.

Dr. Ryan: What do we know about canine OA today that we didn’t know 5 years ago?

Dr. Perkowski: We better understand the progressive nature of the disease and the importance of starting treatment early, before the appearance of clinical signs that an owner might recognize. And we know that it’s a multifactorial disease. 

Dr. Kirkby Shaw: Now we recognize OA as a whole-body disease. From a treatment standpoint, we are going to address the entire body, not just the joint that is affected. 

Dr. Lascelles: As a profession, we are not good at identifying early signs of OA. They are there, but they’re not obvious because these dogs are still moving and are relatively happy. But if you look carefully, many dogs with developmental disease are working really hard to avoid using painful joints. Even subtle changes in body carriage involve a lot of work by the individual animal, indicating a significant problem the pet is trying to avoid. Additionally, we now know that dogs with OA can develop central sensitization quickly after the onset of pain.

Dr. Ryan: How does OA impact the dog’s overall health and how does this vary by OA stage? 

Dr. Lascelles: Across the stages you’ve got progressive deterioration of the musculoskeletal system. (See Table.) The muscle tension associated with the pain and progressive muscle atrophy that’s most obvious in one limb will progress to other parts of the body. You’ve also got progressive deterioration of the somatosensory system across those stages. The final thing, which we do not really appreciate or understand, is the cognitive decline, anxiety, and fear that are happening progressively throughout these stages. 

TABLE

Stages of Canine Osteoarthritis

StageDescription
1At-risk dogs; an observant, trained veterinarian can detect clinical signs; a perceptive owner also might notice signs
2Intermittent, obvious signs (eg, a “weekend warrior” type); obvious impairment of ability to perform certain daily activities that often triggers a visit to the veterinarian; consistent, obvious alterations in body carriage and the beginnings of apparent muscle loss
3Consistent impairment of form and diminished capacity to engage in activities of daily living
4Mobility impairment; clearly diminished ability to move or jump relative to previous normal activity

Dr. Epstein: It is critical to understand the consequences of under-recognized and under-managed OA.  As the disease progresses, dogs are increasingly unable to engage in their normal daily activities, which can have a substantial impact on their lives. OA is a multifaceted, multidimensional, progressive disease that requires intervention with a multimodal treatment approach, preferably early in the process.

Dr. Perkowski: Chronic inflammation sets up throughout the whole body. It’s not just a single joint, it’s a whole-body disease. It’s important to decrease inflammation early.

Assessing for OA

Dr. Ryan: Do you use CMIs to help with OA diagnosis?

Dr. Kirkby Shaw: We use a CMI for patients that come in through the rehab service. From day 1, they complete the CMI to start with an objective point in time. Then we put together a plan and have the clients fill it out regularly.

Dr. Epstein: The CODI is done by interview. It doesn’t measure pain but rather abilities and disabilities, which are progressive. An advantage to the CODI is that we can get an update over the phone. The CBPI is now used by the FDA to measure the efficacy of new OA products. This is what we’re using now as an outcome measure rather than the force plate.

Dr. Lascelles: The off-the-shelf CMIs take less than 2 minutes to complete by the owner and can be done in the waiting room. We use the LOAD, which is the most responsive of these CMIs, in combination with a goal attainment scaling approach like the CSOM questionnaire.

Dr. Kirkby Shaw: The force plate and the CBPI are measuring two separate things. If we are looking at a whole-body disease that is measured by the dog’s change in function and behavior (what chronic pain is measured by), we should use a validated CMI such as the CBPI. To assess weight bearing through an individual limb, the force plate is a more valuable tool.

Dr. Ryan: If you have an owner who is reluctant to do a full workup, what is your go-to diagnostic test for OA?

Dr. Kirkby Shaw: My best diagnostic tool is my orthopedic exam, which begins by taking a thorough history, then watching the dog move around the exam room and studying its transitions (down to stand, stand to sit, etc) before I ever touch it. I also rely on palpation to assess muscle symmetry and soft tissue structures remote from the joints.

Dr. Perkowski: I also palpate the spine along either side of the back and neck.

Dr. Lascelles: Observation first, then orthopedic evaluation. I observe the dog’s resting position, standing position, body carriage, and the way it moves; that almost tells you everything you need to know. With the orthopedic evaluation, muscle atrophy is the most important aspect. 

Dr. Epstein: The lumbosacral joint is often affected. It won’t be apparent unless you actually perform dorsoflexion of the tail while applying digital pressure at the lumbosacral joint. 

Educating the Owner

Dr. Ryan: If somebody brings a dog in that they think is normal but you’ve determined the dog has OA, how do you communicate and educate an owner that the dog needs treatment?

Dr. Lascelles: I don’t downplay the fact that I have made a diagnosis of OA or that I have a high suspicion, but I immediately follow up with the message that if we act aggressively now with a multimodal approach, we may help prevent problems in the future. You want to approach it in an optimistic way—not “Oh, your dog has OA; it’s a lifelong disease. It’s only going to get worse.” We need to change that around but still communicate the gravity. I talk about a window of opportunity and ask them to work with me for 3 to 4 months. If you overemphasize that this is a lifelong disease with very little that can be done, you end up being overly pessimistic. 

Dr. Kirkby Shaw: But what happens after 3 or 4 months? Do you follow up?

Dr. Lascelles: After those few months, they see the benefits. Most are on board for lifelong management.

Dr. Epstein: I’m in primary care, so these patients are usually coming in for an annual visit in which we learn that the dog has become symptomatic in subtle or more obvious ways. We talk about all of these other things in the 10 minutes that we have, but I tell the owners that everything I’m hearing and seeing tells me their dog is developing early signs of OA. I send them home with a trial of an anti-inflammatory and tell them I’ll be in touch in a few days for them to tell me how the pet did with this medication. Then we map out a treatment plan that we’ll continue to talk about for the rest of its life. Dispensing that trial of an anti-inflammatory analgesic is like proof-of-concept that the dog is symptomatic for disease.

Dr. Lascelles: If I see the signs and the client is not quite sure, then I will absolutely do that trial of an analgesic. But I will ask them to look at very specific things, such as the dog with a rounded back due to hip OA. I’ll say, “Just watch that over the next few weeks and let’s see if that rounded back flattens out. We’ll try this and see what happens.” It’s 2 to 4 weeks of an analgesic, and they come back for a revisit. We talk about any adverse events and do another evaluation, possibly repeat blood work. If they’re not responding to that medication, I switch to another.

Weight, Exercise, Rehab, & Pharmaceuticals

Dr. Ryan: What nonpharmacologic approaches do you use to see dogs through from mild through severe disease?

Dr. Lascelles: In younger dogs, I see these as preventive measures versus the therapeutic measures you take in the older dog. Across the stages, exercise moves from preventive into therapeutic, and the type of exercise varies across the different stages. Consistent, sustained exercise is critical—about 1 hour of leash-walking a day. Sustained exercise is a great preventive. For a therapeutic program, the underwater treadmill is useful. Use the water just to get them up and get the legs moving to reduce lameness and improve their ability to perform activities of daily living.

Dr. Epstein: We can’t overemphasize weight management. Adipose tissue is the body’s largest endocrine organ. Everything it secretes is nasty, and it bathes the body in a soup of proinflammatory cytokines. It accelerates or sustains the inflammation in the synovium, which increases the production of prostaglandins as well as catabolic enzymes, which speed up the degradation of cartilage. 

Dr. Kirkby Shaw: For anyone who sees dogs with OA, it is important to recommend regular, controlled, low-impact exercises. Involving someone who is trained in canine rehabilitation can be very valuable. It is important that a veterinarian trained in rehabilitation establishes a whole-body rehab diagnosis and develops a customized plan for the individual dog.  Veterinary technicians and human physical therapists certified in canine rehabilitation may also be involved in the care of dogs with OA. Underwater treadmill therapy, land based exercises, and other modalities will be used to help maintain mobility and functional independence.

Dr. Lascelles: What are your thoughts on the lifelong value of starting a consistent exercise regimen in young dogs?

Dr. Kirkby Shaw: In a young dog with open growth plates, it’s beneficial to encourage normal puppy play but not running or high-impact jumping. You also want to establish the habit of walking, obedience training, and capturing certain behavioral traits, like sitting and standing at attention. 

Dr. Perkowski: Because OA is progressive, it’s important to start treating early and to think about weight management and exercise. Having good muscle mass helps stabilize the joints. 

Dr. Ryan: How are medications initially incorporated in dogs with early OA?

Dr. Perkowski: For dogs showing early or intermittent signs of OA, I recommend initiating treatment rather than waiting until after the dog is limping.

Dr. Kirkby Shaw: Adequan® Canine (polysulfated glycosaminoglycan) is effective when started early in the OA disease process. I start dogs on it as soon as I have diagnosed OA. Ideally we are identifying early OA/DJD in young dogs with developmental orthopedic disease.

Click here to get more information on Adequan.

The Multimodal Treatment Approach

Dr. Ryan: What does your overall multimodal treatment plan look like for a dog with OA?

Dr. Epstein: I start off with NSAIDs. Weight optimization is also right up there, and from a preventive standpoint, it’s probably the number one most important. I also reach for a disease-modifying osteoarthritis agent—specifically Adequan Canine, from an evidence-based perspective.* EPA-rich diets and therapeutic exercise are in there.

The cornerstone of treatment is the alleviation of pain, and I am adamant that it needs to be addressed using predictably efficacious analgesics.—Dr. Lascelles

Dr. Perkowski: NSAIDs are the cornerstone, first line of defense.

Dr. Lascelles: The cornerstone of treatment is the alleviation of pain, and I am adamant that it needs to be addressed using predictably efficacious analgesics. Up until now, the only predictably efficacious class of drugs has been NSAIDs. Now we have the piprants in addition to COX-inhibiting NSAIDs. Weight management, diet optimization, exercise, keeping on top of the animal’s level of discomfort—those are difficult conversations to have, and they’re difficult for a practice to monetize.

Dr. Kirkby Shaw: It’s important to watch a dog’s weight and keep it active. Depending on the age of the dog, regular, controlled, low-impact exercise is absolutely crucial, ideally on a daily basis. Weight loss, nutrition, and disease- modifying drugs take time to take effect, which is one of the reasons that NSAIDs are a cornerstone. And we need to get on top of pain as soon as we can, to try and avoid central sensitization. With an NSAID or PRA, we can have a result within 24 hours in many cases, especially for dogs that are clinically affected. 

Dr. Perkowski: But you don’t want to overwhelm the owner. They are going to hear the first 3 things you tell them and everything thing else will go out the other ear.

Dr. Epstein: I follow up with an email. 

Dr. Lascelles: There is great opportunity for creating educational materials. The veterinarian can provide them in a way that the owner perceives as the veterinarian adding value to the relationship. An interactive digital platform can also connect the owner and the veterinarian. 

Dr. Kirkby Shaw: As a profession, we need to bring client education back to us instead of coming from the pet food store or the trainer or the Internet. We really need to bring that value back into the veterinary clinic.

The Value of Analgesics

Dr. Ryan: You’ve mentioned that NSAIDs are a key aspect of OA treatment. What are your thoughts on intermittent versus continuous NSAID dosing?  

Dr. Epstein: There’s convincing evidence for the advantage of continued dosing over intermittent doses. In 2 separate studies with dogs getting daily doses of NSAIDs over 6 months and a year, they kept getting better over that entire time.1,2 It’s not just a matter of reducing inflammation; you’re also reducing peripheral and central sensitization that arises as a consequence of chronic inflammation. 

Dr. Kirkby Shaw: The Galliprant® (grapiprant tablets) trial data support that. If you look at the results of the CBPI, dogs on the study drug (Galliprant) showed continued statistically significant improvement at 7, 14, 21, and 28 days.† In other words, dogs continued to show improvement over the entire month studied.3

Click here to get more information on Galliprant.

Dr. Lascelles: Yes, if there is pain the treatment should be prolonged—which means daily, approved doses of an effective analgesic, whether that be an NSAID or a piprant. But we also have to remember that everything is plastic and that plasticity can go in both positive and negative directions. We talk about central nervous system plasticity and central sensitization, but the musculoskeletal system is also plastic. As you provide that pain relief, you may have the opportunity to reduce the dose of analgesic.

Dr. Epstein: For the symptomatic patient, there is evidence that daily doses given long-term seem to be advantageous over using them intermittently.1,2

There’s convincing evidence for the advantage of continued dosing over intermittent doses. In 2 separate studies with dogs getting daily doses of NSAIDs over 6 months and a year, they kept getting better over that entire time.1,2—Dr. Epstein

Dr. Perkowski: If you’re going to see an adverse event with an NSAID, it typically happens within the first few weeks. It doesn’t necessarily mean you’re going to have one with another nonsteroidal. Most likely, I wouldn’t keep a dog on a full label dose for a year, even though there is a paper that says it’s okay. I would like it to be at the lowest dose necessary to provide the changes I’m looking for—and that’s not just pain. It might be effusion in the stifle or other signs of inflammation.

Consequences of OA

Dr. Ryan: What are the consequences of waiting to treat patients until the OA is advanced?

Dr. Lascelles: When I see dogs with advanced OA, there is often significant deterioration of the musculoskeletal system, the sensory system, and the affective system (fear, feeling, anxiety). I often think that earlier treatment would have benefited these patients.

Dr. Perkowski: As OA progresses, destructive metalloproteinases and other inflammatory cytokines and prostaglandins are produced in the joint. 

Dr. Kirkby Shaw: It’s much harder to treat once chronic pain has set in.

Dr. Perkowski: Treating OA early is a real game-changer. It takes your analgesia protocol to the next level. Galliprant provides another treatment option for veterinarians that can be used as soon as OA is diagnosed.

Dr. Lascelles: The goal of a multimodal treatment plan is to prevent that cycle of deterioration from being initiated and getting a grip. Once that has started, it’s really difficult to pull them back. Galliprant is one option that might make veterinarians feel comfortable about treating pain early.

Dr. Ryan: So one of the benefits of Galliprant is that it’s a good tool that veterinarians can use to treat OA early?

Dr. Epstein: We are veterinarians and we, above all, want to do no harm, but that mindset has created a circumstance where we’re undermanaging pain because of our perceptions of risk and not managing in such a way that maximizes the benefit for the patient. All treatments have side effects that must be considered when prescribing a chronic OA medication. A PGE2 EP4 receptor antagonist, such as Galliprant, may give us the confidence to do what we should. 

Dr. Lascelles: There is this embedded fear of treating OA in young dogs, particularly with prescription products intended for chronic use.

Dr. Perkowski: The nonsteroidals are a heterogeneous mix of molecules that are grouped together because they inhibit the COX enzymes. Galliprant is a non-COX inhibiting PRA that specifically targets the EP4 receptor downstream of these enzymes.

Dr. Epstein: The EP4 receptor is largely but not exclusively responsible for the pain and inflammation of OA. The EP1, EP2, and EP3 receptors are largely but not exclusively responsible for gastrointestinal and renal homeostasis. That’s why a downstream action can target pain and inflammation while reducing the impact on GI, kidney, and liver homeostatic functions that are mediated by PGE2. The safety study is remarkable. In 36 young, healthy dogs given Galliprant at 15 times the approved daily dose for 9 months, there were no pathological changes detected within the kidneys or liver of any dog, nor were there any ulcerations detected in the GI tract, including the stomach.4,5 Gastrointestinal signs that occurred were all self-limiting; no dog was treated, the drug was not withdrawn, and the patients weren’t withdrawn. It is fair to say that the safety data are impressive.

Dr. Lascelles: I agree with all of those comments. The ability to treat pain associated with OA early and chronically is beneficial. One of the exciting things about Galliprant is that it can do both. 

Dr. Ryan: NSAIDs are known for their GI effects. What are the implications for veterinarians prescribing Galliprant for OA treatment? 

Dr. Kirkby Shaw: Vomiting is one of the most common side effects for all NSAIDs, including Galliprant. With Galliprant, this isn’t thought to be a pathologic process in the stomach or duodenum. It’s potentially a motility issue, based on the mechanism of action of the PGE2 EP4 receptor.6 The safety study showed that vomiting was not associated with pathologic changes. 

Dr. Epstein: As a clinician, if you have a patient on a COX-inhibiting nonsteroidal, you tell the owner to stop the drug and call you if the dog vomits. Then you probably put the dog on some gastroprotectant out of an abundance of caution. Maybe the vomiting was due to the NSAIDs, maybe not.

I’m going to choose Galliprant® (grapiprant tablets) as a first-line option for my OA cases.—Dr. Kirkby-Shaw

Dr. Ryan: Do you have owners call you after just a single occasion of vomiting?

Dr. Epstein: Yes, but it seems that you don’t necessarily need to withdraw Galliprant if vomiting occurs.

Dr. Kirkby Shaw: As I gain experience with this new product, I do ask my clients to call if any vomiting occurs, but I do not necessarily discontinue Galliprant. The Galliprant client insert doesn’t say anything about contacting your vet or stopping the medication for vomiting. It does say to call if there is a change in stool consistency or appetite, but it doesn’t say to stop the medication.

Dr. Lascelles: Even with Galliprant, if there is vomiting, I proactively ask the owner to call me. If it’s a single episode and the dog is bright, alert, eating, and drinking, I will probably continue with the Galliprant. If there have been a couple of episodes of vomiting, I will probably stop the drug and reintroduce it 2 days later. I feel better about keeping the drug going, but I’m still going to take what I consider a sensible approach to it. I have seen no reason to use gastroprotectants under those circumstances.

Dr. Kirkby Shaw: EP4 is not involved in acid secretion in the stomach, so giving an antacid is probably not going to make a big difference.

Dr. Ryan: Where are you using Galliprant? In what patients?

Dr. Kirkby Shaw: I’m going to choose Galliprant as a first-line option for my OA cases. Also, I am switching dogs that don’t seem to be responding to traditional NSAIDs efficacy-wise. 

Dr. Epstein: I am using Galliprant primarily as a first-line therapy, but I’m also including OA patients assessed as NSAID-intolerant for one reason or another. 

Dr. Lascelles: Yes, my preference is to use it in ever-expanding circles within my OA patient population. So I’m starting with regular OA cases, the dogs in which I would use NSAIDs. Once I get comfortable there, I will then expand out to other OA patients, cases that may be considered higher risk  for traditional therapies.

Dr. Perkowski: I’m trying it in patients in which I might have normally used a COX-inhibiting NSAID and seeing what the efficacy is like.Once I get to a certain comfort level, I may start to expand my use to other OA cases. 

Dr. Ryan: What does Galliprant mean for the future of OA treatment? 

Dr. Kirkby Shaw: This is the first time in 20 years that we have an anti-inflammatory with a new mechanism of action. We now have this targeted effect that is sparing all of the prostanoids (prostaglandin E, I, D, F2 alpha, and thromboxane) and allowing them to maintain their homeostatic roles throughout the body. We can target the one receptor that’s most important in transmitting pain and inflammation—the one shown to be upregulated in the joint and the dorsal root ganglion in chronic pain states.7 

Dr. Epstein: From an evidence-based perspective, nonsteroidals occupy the top tier in terms of a quick and predictable response. On the other hand, we’re not intervening early enough. We’re not using NSAIDs as aggressively as the evidence suggests we should be, because we fear adverse events. With Galliprant we have a new class that should give us confidence to alleviate pain and inflammation in a way that we know will benefit patients.

Dr. Perkowski: Galliprant is the next generation of OA pain management. This is taking it to the next level. The future is here.


Galliprant® (grapiprant tablets)

Indication

Galliprant® (grapiprant tablets) is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. Keep this and all medications out of reach of children and pets. For use in dogs only. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see accompanying full prescribing information.

Adequan® Canine (polysulfated glycosaminoglycan)

Indication

Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

Important Safety Information

Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post-approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy, and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant, or lactating dogs has not been evaluated. Please see accompanying full prescribing information. 


CBPI = Canine Brief Pain Inventory, CMI = Clinical metrology instrument, CODI = Canine Orthopedic Disability Index, COX = Cyclo-oxygenase, CSOM = Client-specific outcomes measures, DJD = Degenerative joint disease, EP = Prostanoid receptors sensitive to prostaglandin E2, EPA = Eicosapentaenoic acid, GI = Gastrointestinal, LOAD = Liverpool Osteoarthritis in Dogs, MAP = Mitogen-activated protein, NF-kB = Nuclear factor kappa-light-chain enhancer of activated B cells, NSAID = Nonsteroidal anti-inflammatory drug, OA = Osteoarthritis, PG = Prostaglandin, PRA = Prostaglandin receptor antagonist, PSGAG = Polysulfated glycosaminoglycan, TXA = Thromboxane

References Show
References
  1. Autefage A, Palissier FM, Asimus E, Pepin- Richard C. Long-term efficacy and safety of  firocoxib in the treatment of dogs with osteoarthritis. Vet Rec. 2011; 168(23):617.
  2. Autefage A, Gossellin J. Efficacy and safety of the long-term oral administration of carprofen in the treatment of osteoarthritis in dogs. Revue Med Vet. 2007; 158(3):119-127.
  3. Rausch-Derra L, Huebner M, Wofford J, Rhodes L. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med. 2016;30(3):756-763.
  4. Rausch-Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Am J Vet Res. 2015; 76(10):853-859.
  5. Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Therap. 2016; 39:566-571.
  6. Takeuchi K, Kato S, Amagase K. Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J Pharmacol Sci. 2010; 114:248-261.
  7. Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015; 2:3-9.

Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Up Next